Our approach is to bring payers, patients, researchers, doctors, and biotech companies together with impact investors to cure specific diseases. With a clear goal of measurably improving specific patient outcomes in 10 years, and new resources from impact investors and payers, Mission: Cure will deploy the most promising and cost-effective methods to develop new therapies and bring them to patients.

Financing Based On Patient Outcomes
Linking payment to patient outcomes such as hospitalizations, longevity and pain incentivizes activities that make a real difference for people suffering from the disease.
Promising And Cost-Effective Methods To Cure Diseases
Our approach leverages advanced genomics and precision medicine to understand disease causes and target therapies including repurposing approved medicines to get therapies to patients faster.
Active Collaboration Among Stakeholders
Clear, shared goals and a defined timeframe provide a collaborative framework for key stakeholders to produce results. Stakeholders include: impact investors, patients, industry, scientists and clinicians, payers, philanthropists, and government.
Partnerships With Impact Investors
We work with the growing group of impact investors who want their money to produce social benefits in addition to financial return. Investors can see their impact on people’s health and receive a return from patient outcome payments and the market.

Who benefits?

Patients

will be able to prevent or treat their disease so they are no longer in pain and live longer, healthier, more productive lives.

Impact Investors

will have helped cure a disease and potentially have received a financial return.

Scientists and Clinicians

will have sufficient funding and support to pursue and succeed in their efforts to help patients and cure disease.

Healthcare and Other Payers

will be able to invest in new treatments that reduce their long‐term costs, while demonstrating their commitment to their clients’ wellbeing, by contributing to patient outcome payments.

Venture Philanthropists

will engage in what amounts to risk‐free outcome‐based philanthropy: they will not pay unless the efforts they support have delivered the results they hoped for.